Concepedia

I. Kawabata

IK

Statistics

Publications

2

Citations

27

H-Index

2

Active since

2014

Affiliations

Shionogi (Japan)(Current)

Guy's Hospital

King's College London

I. Kawabata is an author at Shionogi (Japan) specializing in tyrosine kinase inhibitors, tyrosine kinase inhibitor therapy, and egfr inhibition.

Publications per year

2014–2018

2

Publications

2

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours

James Spicer, Richard D. Baird, Aneta Suder et al. · European Journal of Cancer · 2014 · 15 citations · Full text

, , +13

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

Hendrik‐Tobias Arkenau, Antoîne Italiano, Gabriel Mak et al. · European Journal of Cancer · 2018 · 12 citations

, , +11

1–2 of 2